159 related articles for article (PubMed ID: 27405794)
1. Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
Giesler KE; Marengo J; Liotta DC
J Med Chem; 2016 Aug; 59(15):7097-110. PubMed ID: 27405794
[TBL] [Abstract][Full Text] [Related]
2. Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
Giesler KE; Liotta DC
J Med Chem; 2016 Nov; 59(22):10244-10252. PubMed ID: 27933889
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Modified Amidate (ProTide) Prodrugs of Tenofovir with Enhanced Antiviral Properties.
Kalčic F; Zgarbová M; Hodek J; Chalupský K; Dračínský M; Dvořáková A; Strmeň T; Šebestík J; Baszczyňski O; Weber J; Mertlíková-Kaiserová H; Janeba Z
J Med Chem; 2021 Nov; 64(22):16425-16449. PubMed ID: 34713696
[TBL] [Abstract][Full Text] [Related]
4. Flexibility-Not just for yoga anymore!
Seley-Radtke K
Antivir Chem Chemother; 2018; 26():2040206618756788. PubMed ID: 29466861
[TBL] [Abstract][Full Text] [Related]
5. ω-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.
Pribut N; D'Erasmo M; Dasari M; Giesler KE; Iskandar S; Sharma SK; Bartsch PW; Raghuram A; Bushnev A; Hwang SS; Burton SL; Derdeyn CA; Basson AE; Liotta DC; Miller EJ
J Med Chem; 2021 Sep; 64(17):12917-12937. PubMed ID: 34459598
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antiviral evaluation of base-modified deoxythreosyl nucleoside phosphonates.
Liu C; Dumbre SG; Pannecouque C; Korba B; De Jonghe S; Herdewijn P
Org Biomol Chem; 2017 Jul; 15(26):5513-5528. PubMed ID: 28628181
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antiviral evaluation of 2-amino-6-carbamoylpurine dioxolane nucleoside derivatives and their phosphoramidates prodrugs.
Cho JH; Bondana L; Detorio MA; Montero C; Bassit LC; Amblard F; Coats SJ; Schinazi RF
Bioorg Med Chem; 2014 Dec; 22(23):6665-6671. PubMed ID: 25458500
[TBL] [Abstract][Full Text] [Related]
8. Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication.
Liu C; Dumbre SG; Pannecouque C; Huang C; Ptak RG; Murray MG; De Jonghe S; Herdewijn P
J Med Chem; 2016 Oct; 59(20):9513-9531. PubMed ID: 27748590
[TBL] [Abstract][Full Text] [Related]
9. Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.
Tang YB; Peng ZG; Liu ZY; Li YP; Jiang JD; Li ZR
Bioorg Med Chem Lett; 2007 Nov; 17(22):6350-3. PubMed ID: 17888662
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
[TBL] [Abstract][Full Text] [Related]
11. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
Margot NA; Liu Y; Miller MD; Callebaut C
Antiviral Res; 2016 Aug; 132():50-8. PubMed ID: 27208653
[TBL] [Abstract][Full Text] [Related]
12. Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells.
Beadle JR; Kini GD; Aldern KA; Gardner MF; Wright KN; Richman DD; Hostetler KY
Antivir Chem Chemother; 1998 Jan; 9(1):33-40. PubMed ID: 9875375
[TBL] [Abstract][Full Text] [Related]
13. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
Zhu Y; Curtis M; Qi X; Miller MD; Borroto-Esoda K
Antivir Chem Chemother; 2009; 19(4):165-76. PubMed ID: 19374144
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of new 2'-deoxy-2'-fluoro-4'-triazole cytidine nucleosides as potent antiviral agents.
Wu J; Yu W; Fu L; He W; Wang Y; Chai B; Song C; Chang J
Eur J Med Chem; 2013 May; 63():739-45. PubMed ID: 23570720
[TBL] [Abstract][Full Text] [Related]
15. Modeling the functional state of the reverse transcriptase of hepatitis B virus and its application to probing drug-protein interaction.
Xu X; Thai H; Kitrinos KM; Xia G; Gaggar A; Paulson M; Ganova-Raeva L; Khudyakov Y; Lara J
BMC Bioinformatics; 2016 Aug; 17 Suppl 8(Suppl 8):280. PubMed ID: 27587008
[TBL] [Abstract][Full Text] [Related]
16. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.
Delaney WE; Ray AS; Yang H; Qi X; Xiong S; Zhu Y; Miller MD
Antimicrob Agents Chemother; 2006 Jul; 50(7):2471-7. PubMed ID: 16801428
[TBL] [Abstract][Full Text] [Related]
17. Asymmetric synthesis and antiviral activities of L-carbocyclic 2', 3'-didehydro-2',3'-dideoxy and 2',3'-dideoxy nucleosides.
Wang P; Gullen B; Newton MG; Cheng YC; Schinazi RF; Chu CK
J Med Chem; 1999 Aug; 42(17):3390-9. PubMed ID: 10464025
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and anti-hepatitis B activity of new substituted uracil and thiouracil glycosides.
Abdel-Aal MT
Arch Pharm Res; 2010 Jun; 33(6):797-805. PubMed ID: 20607483
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of erythrocentaurin derivatives as a new class of hepatitis B virus inhibitors.
Geng CA; Huang XY; Ma YB; Zhang XM; Chen JJ
Bioorg Med Chem Lett; 2015 Apr; 25(7):1568-71. PubMed ID: 25737009
[TBL] [Abstract][Full Text] [Related]
20. Ester prodrugs of acyclic nucleoside thiophosphonates compared to phosphonates: synthesis, antiviral activity and decomposition study.
Roux L; Priet S; Payrot N; Weck C; Fournier M; Zoulim F; Balzarini J; Canard B; Alvarez K
Eur J Med Chem; 2013 May; 63():869-81. PubMed ID: 23603046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
